Hematopoietic stem cells (HSCs) ensure a life-long regeneration of the blood system and are therefore an important source for transplantation and gene therapy. The teratoma environment supports the complex development of functional HSCs from human pluripotent stem cells, which is difficult to recapitulate in culture. This model mimics various aspects of early hematopoiesis, but is restricted by the low spontaneous hematopoiesis rate. In this study, a feasible protocol for robust hematopoiesis has been elaborated. We achieved a significant increase of the teratoma-derived hematopoietic population when teratomas were generated in the NSGS mouse, which provides human cytokines, together with co-injection of human umbilical vein endothelial cells. Since little is known about hematopoiesis in teratomas, we addressed localization and clonality of the hematopoietic lineage. Our results indicate that early human hematopoiesis is closely reflected in teratoma formation, and thus highlight the value of this model.
INTRODUCTION
Tissue stem cells are the life-long source of organ regeneration. Unlike the origin of solid tissue, development of the hematopoietic stem cells (HSCs) proceeds through distinct stages during embryogenesis (Godin and Cumano, 2002; Mikkola, 2006) . The definitive HSCs in vertebrates emerge during a process called endothelial-to-hematopoietic transition (EHT), from hemogenic endothelium (Bertrand et al., 2010; Kissa and Herbomel, 2010) . Due to their long-term self-renewal capacities, HSCs are valuable for gene and cell therapies (Morgan et al., 2017) . Although many aspects of HSC biology have been elucidated, it remains difficult to generate, maintain, or expand human HSCs. The possibility for de novo generation from human induced pluripotent stem cells (hiPSCs) would especially help to relieve the limitation of donor material.
Most differentiation protocols for modeling hematopoiesis are based on small molecules, cytokine supplementation, and timed expression of transcription factors (TFs), following general lines of developmental steps from PSCs to hematopoietic progenitors (Sugimura et al., 2017; Vo and Daley, 2015) . These important models, however, fail to mimic the complexity of the cellular environment necessary to support HSC development. The teratoma formation assay offers a three-dimensional (3D) embryonic microenvironment with corresponding tissue patterning, epigenetic imprinting, and extracellular matrices (Damjanov and Andrews, 2016; Gertow et al., 2004) . In this surrounding, a low level of spontaneous hematopoiesis occurs and gives rise to engraftable hematopoietic progenitors (Amabile et al., 2013; Suzuki et al., 2013) . Implanted osmotic pumps delivering cytokines, such as thrombopoietin and stem cell factor (SCF), can increase the level of hematopoiesis in teratomas (Suzuki et al., 2013) . Other protocols use co-injection of murine bone marrow stromal cells (OP9) together with hiPSCs. Further improvement was achieved by the co-injection of genetically modified OP9 expressing Notch ligand Delta-like 1 (Dll1) or Wnt3a (Amabile et al., 2013; Suzuki et al., 2013) . Alternatively, murine iPSCs, equipped with an inducible TF (Gfi1b), led to elevated hematopoietic levels after administration of doxycycline (Tsukada et al., 2017) . To overcome technical hurdles such as implantation of osmotic pumps, we developed a feasible and less demanding teratoma assay as a robust model for hematopoiesis.
Currently little is known about the origin or maintenance of human hematopoietic cells in teratomas. H&E staining identified hematopoietic cell phenotype in bone marrowlike structures in teratomas (Amabile et al., 2013) . Others showed putative hematopoietic cells to reside in close proximity to liver cells, mesenchymal stroma, or yolk sac structures (Damjanov and Andrews, 2016) . In a murine iPSC teratoma system, there is evidence that hematopoiesis occurs by EHT (Tsukada et al., 2017) . Using our optimized system for human hematopoiesis, we extensively evaluated the origin and cellular environment of human hematopoietic cells in teratomas via detailed multicolor fluorescent immunohistochemistry (IHC).
To use teratomas to investigate processes of human embryogenesis or hematopoiesis, improved characterization of clonal development is necessary. Blum and Benvenisty (2007) addressed this by mixing three human embryonic stem cell (hESC) lines for teratoma induction. Microsatellite signatures in microdissections of teratoma structures revealed a mixed composition of hESC lines, indicating a polyclonal origin. This important finding illustrates the high impact of environmental cues on differentiation rather than clonal preferences. In our study, we used lentiviral genetic barcode labeling to monitor several thousand clones throughout teratoma development with specific emphasis on hematopoiesis.
In summary, this study provides detailed analysis of hematopoietic teratoma cell localization and clonal development as well as a feasible protocol to generate elevated hematopoiesis levels.
RESULTS

Low Rate of Hematopoiesis in Subcutaneous Teratomas in NSG Mice
To test the level of spontaneous hematopoiesis in teratomas, we injected 1-5 3 10 6 CD34-derived hiPSCs (CD34hiPSC16) subcutaneously into the flanks of NSG mice. Teratomas were isolated once they reached a diameter of about 1.5 cm, which took 45 ± 8 days (mean ± SD). Quantification of hematopoietic cells was accomplished by flow cytometry (FC). To exclude false-positive results due to antibody cross-reactions with damaged cells, we applied a gating strategy that relied upon viability staining and isotype controls ( Figure S1A ). Overall, teratomas (n = 3) displayed a low spontaneous rate of hematopoietic differentiation ( Figure 1A ). IHC staining of teratoma sections for the specific markers confirmed low abundance of CD45 + cells ( Figure 1B ). Of note, CD34 expression occurred in cell clusters whereas the rare CD45 + hematopoietic cells were found distributed throughout the tissue ( Figure 1B ).
Co-injection of HUVECs Supports Hematopoiesis in Teratomas
Due to the low rate of CD45 + cells in NSG mice and to better mimic a suitable environment for hematopoiesis in the teratoma, we co-injected either human umbilical vein endothelial cells (HUVECs) or murine stromal cell line OP9 together with hiPSCs. The latter are known to elevate hematopoietic output in teratomas (Amabile et al., 2013; Chen et al., 2015; Suzuki et al., 2013) . HUVECs were selected because of their instructive signals for the development of hematopoietic cells from vascular endothelium in vitro (Gori et al., 2015; Lis et al., 2017) . We applied 5 3 10 6 hiPSCs and 1 3 10 6 of the respective supporter cell type for these co-injection experiments. Co-transplantation of OP9 (n = 4) generated a human CD34 À /CD45 + population with a median below 0.5% ( Figure 1C ). Coinjection of HUVECs (n = 6) resulted in a hematopoietic population with a median of 0.7%. In contrast to former teratoma studies (Amabile et al., 2013; Suzuki et al., 2013) , our FC analyses detected no migration of hiPSCderived CD34 + or CD45 + hematopoietic cells in peripheral blood (PB) or bone marrow (BM) of teratoma-bearing mice.
Elevated Levels of Hematopoietic Cells by Systemic Administration of Human Cytokines
Since co-injection experiments did not efficiently increase hematopoiesis, we explored whether cytokine application can be supportive in this setting. Human interleukin-3 (IL-3), granulocyte macrophage-colony stimulating factor (GM-CSF), and SCF foster hematopoietic progenitor maintenance and expansion (Lemoli and Gulati, 1993) . Instead of additive cytokine administration we employed NSGS mice, which systemically express all three cytokines in the NSG mouse background. Teratomas induced with hiPSCs alone (n = 6) in NSGS showed a median of 1.2% hematopoietic cells (CD34 À /CD45 + ) ( Figure 1D ). These results were reproducible for a human newborn foreskin fibroblast-derived (Nuff-hiPSC) hiPSC clone. The hematopoietic population comprised a median of 0.9% CD34 À / CD45 + cells (n = 2), comparable with teratomas generated with hiPSCs ( Figure 1D ). Encouraged by these results, we tested whether the contribution of hematopoietic cells could be increased by co-injection of OP9 (n = 4) or HUVECs (n = 5). Indeed, we saw synergistic effects of the supporter cells and cytokine background ( Figure 1D ). HUVEC co-transplanted teratomas contained a significantly larger hematopoietic population (CD34
with a median of 6.1% than teratomas generated in NSGS mice with hiPSCs alone (1.2%). Although the level of hematopoietic cells was elevated, no evidence for migration of hiPSC-derived hematopoietic cells was detected in these experiments by FC (PB and BM).
Notch Ligands and WNT3A Overexpressed by HUVECs Do Not Further Promote Hematopoiesis
Although the exact mode of action through which Notch and Wnt3a signaling affect hematopoiesis remain to be fully elucidated, studies do support the importance of both pathways for hematopoiesis (Bigas and Espinosa, 2012; Lento et al., 2013) . Most importantly, Dll1 or Wnt3a expressed by OP9 were previously used to improve hematopoietic output in teratoma assays (Amabile et al., 2013; Suzuki et al., 2013) . To compare the influence of these signaling pathways on hematopoiesis in teratomas, we designed lentiviral vectors to constitutively overexpress WNT3A, DLL1, or DLL4 in HUVECs and OP9 (Figures S1B-S1D). DLL4 was included because it is known to be crucial for arterial specification, representing the starting point for definitive hematopoiesis (Duarte et al., 2004; Park et al., 2018) . In fact, teratomas generated with co-transplanted OP9 expressing DLL1 (n = 3), DLL4 (n = 4), or WNT3A (n = 4) yielded higher CD45 + populations than with OP9 alone ( Figure 1E ). On the other hand, teratomas with co-injected HUVEC-WNT3A resulted in comparable CD45 + populations than with HUVECs alone. Interestingly, HUVEC-DLL1 or -DLL4 did not mediate any hematopoietic support ( Figure 1E ). In summary, teratomas generated in NSGS mice with co-injection of unmodified HUVECs or OP9-DLL1 resulted in an + population of teratomas generated in NSG with hiPSC + OP9 was set to a value of 1. Graph depicts median and range. Statistics of (C), (D), and (F) were calculated by Kruskal-Wallis and Dunn's multiple comparisons tests (*p < 0.05).
80-fold and 86-fold (medians) greater CD45
+ population compared with teratomas generated in NSG mice with co-injected OP9 ( Figure 1F ).
HUVEC Populations Decline during Teratoma Formation
As HUVECs appeared to promote the hematopoietic population in teratomas, we investigated how long HUVECs are present during teratoma formation. Therefore, we generated HUVECs that expressed firefly luciferase (HUVECFluc) and modified hiPSCs to express the fluorescent protein Katushka2S to monitor teratoma growth (Luker et al., 2015) ( Figures S1E and S1F ). Within 7 weeks the bioluminescent signal of the co-injected 1 3 10 6 HUVECFluc decreases to 2.5% of the signal obtained at the day of injection (Figures 2A and 2B ). This suggests that the hemogenic support by HUVECs mainly occurred during the first 2-4 weeks. We further evaluated lineage capacity of isolated CD34 + / CD45 + teratoma cells generated in this setting. Clonogenic assays (n = 6) demonstrated the potential of these cells to produce granulocytes, macrophages, and few immature erythrocytes, which was comparable with freshly isolated CD34 + cord blood cells (n = 3) ( Figures 2C and 2D) . In
Pappenheim staining, cells showed the expected phenotypes of band neutrophils, eosinophils, monocytes, and normoblasts. Sorted CD45 + teratoma populations appeared to consist mainly of monocytes and neutrophils ( Figure 2E ).
Localization of Hematopoietic Cells inside Vascular Structures
To improve the use of teratoma-linked hematopoiesis as a developmental model, we investigated the points of origin and localization of human hematopoietic cells inside the teratomas. We applied IHC staining on teratoma sections to localize hematopoietic sites in our human setting. All antibodies were validated on appropriate positive and negative controls to ensure specificity for human antigens in this xenograft model. Figure 3C ). To validate the endothelial nature of the CD34 + cells, we also stained sections for the endothelial marker CD31 ( Figure 3D ). To obtain a more detailed view of the hemogenic vasculature, we recorded z stacks ($100 mm) of stained teratoma slices and calculated 3D models. This approach visualized hematopoietic cell clusters embedded inside and around CD34 + vessels ( Figure 3E ). Figure S2D ).
Clonality of Teratoma Formation and Hematopoiesis
Currently it remains to be determined whether teratoma development is subject to clonal pressure or how many hiPSCs of the injected culture contribute to teratoma formation and initiate hematopoiesis. In theory, a teratoma can be generated by a single pluripotent cell. Despite the improvement of hematopoiesis rate, the proportion of hematopoietic progenitors in teratomas remained low in the experiments described above. Therefore, we applied RGB (red, green, blue) labeling combined with nucleotide barcoding (Cornils et al., 2014; Selich et al., 2016) to investigate the frequency of iPSCs, which actually undergo hematopoietic differentiation. This method allowed us to trace clones via genetic labeling. Additional expression of mCherry, Venus, or Cerulean (RGB labeling) also facilitated visual assessment of clonal development ( Figure 4A ). Transduced hiPSCs were expanded for 21 days (14.6-fold expansion). Additionally, transgene expression was monitored by fluorescence microscopy and FC during the expansion phase and in isolated teratomas, indicating no major transgene silencing in vitro or in vivo ( Figure 4B ). Samples were harvested and analyzed after transduction, after in vitro expansion, and finally after teratoma formation. The teratoma samples (n = 5) were divided into two sections. One was directly used for sequencing and the second was used to isolate the hematopoietic population by magnetic hCD45 beads followed by sequencing ( Figure 4C ). Deep sequencing data identified a highly polyclonal composition in hiPSC culture, teratomas, and hematopoietic cells ( Figure 4D ). Read counts of identical sequences were used as a surrogate marker for clonal contribution of individual barcodes. We observed that only 146 out of 28,300 measured barcodes reoccurred in all CD45 + hematopoietic samples, and 139 out of 21,698 barcodes were detected in all teratoma samples. Hence, thousands of injected cells are capable of forming teratomas and hematopoietic cells ( Figures 4E and 4F ). In summary, our results suggest that expanded hiPSCs contained a homogeneous pool of cell clones potentially able to form teratomas. Furthermore, several thousand initial hiPSCs revealed the capacity for hematopoietic differentiation. 
DISCUSSION
The teratoma model provides human embryonic tissue to study early hematopoiesis in a physiological 3D environment. However, the CD45 + population in teratomas generated with hiPSCs in NSG mice is low and, thus, hampers its application as a hematopoiesis model. In this study, we elaborated a feasible approach to enhance teratoma-linked hematopoiesis by using NSGS mice. The supply of cytokines by the mouse model is time-saving, easy to perform, and cost-effective. Further enhancement was achieved upon co-injection with supporter cells. HUVECs can promote EHT through vascular induction or support expansion of hematopoietic progenitors from cord blood by secretion of cytokines and growth factors in vitro (Lis et al., 2017; Yamaguchi et al., 1996; Yildirim et al., 2005) .
In the teratoma setting, the presence of HUVECs led to a significant increase in the hematopoietic population in teratomas, although the majority of HUVECs was not maintained beyond 30 days of teratoma formation. Similar levels of hematopoietic cells were obtained with OP9-DLL1, OP9-DLL4, or OP9-WNT3A, but not with OP9 alone. Intriguingly, while co-injection of HUVEC-WNT3A did not further elevate hematopoietic yield compared with HUVECs alone, co-injection of HUVEC-DLL1 or -DLL4 suppressed intra-teratoma hematopoiesis. It remains to be determined whether this was caused by changes in the transcriptome of HUVECs potentially provoked by lentiviral transduction or whether the overexpression of the particular transgenes is not compatible with the support of hematopoiesis by HUVECs. In summary, the elaborated teratoma formation protocol with HUVECs in NSGS mice provides a decent hematopoietic population and represents a starting point from which to investigate human hematopoiesis with a low technical demand.
The explicit polyclonality of teratoma formation and subsequent hematopoiesis makes this system interesting for additional applications. Future studies could use genetic barcode labeling to mark differentially cultured or transduced hiPSC clones to study their differentiation preferences. Microdissections would allow investigation of potential germ-layer preferences exhibited by different hiPSC clones. In particular, upscaling differentiation protocols could be optimized by selecting the most suitable clone for the specific target lineage. Furthermore, effects of TFs from libraries on teratoma-derived hematopoiesis could be examined closely and might promote valuable insights into developmental states even beyond the hematopoietic system.
Another important asset of the teratoma model is the possibility to localize target cells in tissues assembled in natural structures. In this study, human hematopoietic cell localization was carefully examined by specific detection of surface markers. In rare cases, hematopoietic progenitors were located inside vessels. These results indicate that hiPSC-derived hematopoiesis in teratoma reflects the natural EHT process, which has recently been described for murine teratomas (Tsukada et al., 2017 
Teratoma Induction
For injection into mice, hiPSC were harvested using trypsin/EDTA. Unless stated otherwise, cell numbers were adjusted to 3 3 10 6 hiPSCs per injection. In co-injection experiments, 1 3 10 6 supporter cells were mixed with hiPSCs prior to injection. Harvested cells were centrifuged at 300 3 g and gently resuspended in hiPSC medium containing 20 mM Y-27632 (kindly provided by Leibniz University, Hannover). Cell suspensions were cooled to 4 C prior to addition of 100 mL of Matrigel basement membrane matrix (Corning) (Prokhorova et al., 2009 ). The injection solution was kept at 4 C until subcutaneous injection into the flank.
We induced two teratomas per mouse. The injection volume was 150-200 mL. Mice were sacrificed as soon as one teratoma reached 1.5 cm in diameter. After isolation, teratoma tissue was randomly divided into two parts. One was used for IHC and the other for FC. 
Single-Cell Preparation from Teratoma Tissue
Teratomas were sliced into 3-to 5-mm pieces and incubated in DMEM containing 160 U/mL dispase I (Roche) and 2 U/mL collagenase IV (Thermo Fisher Scientific) for 40-60 min at 37
C. Thereafter, suspensions were processed through 70-mm cell strainers (Fisher Scientific). After centrifugation (300 3 g, 10 min, 4 C 
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